Published in J Neurol Neurosurg Psychiatry on December 01, 1990
In vivo imaging of spinal cord atrophy in neuroinflammatory diseases. Ann Neurol (2014) 0.79
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
FURTHER NOTES ON DISABILITY EVALUATION IN MULTIPLE SCLEROSIS, WITH SCALE MODIFICATIONS. Neurology (1965) 2.73
Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain (1989) 2.00
Antibody to human T-lymphotropic virus type 1 in West-Indian-born UK residents with spastic paraparesis. Lancet (1987) 1.92
Distribution of plaques in seventy autopsy cases of multiple sclerosis in the United States. Neurology (1976) 1.51
Leukoencephalopathy in HTLV-I-associated myelopathy: MRI and EEG data. J Neurol Sci (1988) 0.96
HTLV-I positive spastic paraparesis in a temperate zone. Lancet (1989) 0.94
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci (2003) 10.44
Delayed visual evoked response in optic neuritis. Lancet (1972) 6.11
Visual evoked response in diagnosis of multiple sclerosis. Br Med J (1973) 5.61
Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med (1991) 5.33
Diagnosis and classification of multiple sclerosis. Br Med Bull (1977) 4.68
Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet (1997) 4.43
Oral contraceptives and cerebral arterial occlusion. Br Med J (1965) 4.42
Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology (2003) 3.75
Neural correlates of motor recovery after stroke: a longitudinal fMRI study. Brain (2003) 3.65
The effects of experimental demyelination on conduction in the central nervous system. Brain (1970) 3.31
The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
Neural correlates of outcome after stroke: a cross-sectional fMRI study. Brain (2003) 3.04
In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol (1990) 2.70
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67
Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain (1992) 2.62
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology (1999) 2.54
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54
Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain (1990) 2.53
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. J Neurol Neurosurg Psychiatry (2000) 2.44
Superficial siderosis of the central nervous system. Brain (1995) 2.31
Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain (1988) 2.29
Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol (1991) 2.25
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
Paradoxical expansion of intracranial tuberculomas during chemotherapy. Lancet (1984) 2.19
Factors influencing the risk of multiple sclerosis developing in patients with optic neuritis. Brain (1978) 2.19
The pattern-evoked potential in compression of the anterior visual pathways. Brain (1976) 2.07
Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology (2008) 2.06
The clinical picture of ectasia of the intracerebral arteries. J Neurol Neurosurg Psychiatry (1982) 2.05
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
The Functional Independence Measure: a comparative validity and reliability study. Disabil Rehabil (1995) 2.04
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry (2000) 2.01
Mystery of chronic cerebrospinal venous insufficiency: identical venographic and ultrasound findings in patients with MS and controls. AJNR Am J Neuroradiol (2013) 2.01
Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain (2002) 2.01
Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain (1989) 2.00
Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain (1990) 2.00
Immunologic studies in IgA nephropathy. Kidney Int (1980) 1.99
Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ (1990) 1.99
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain (1998) 1.99
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry (2005) 1.97
Magnetic resonance imaging in isolated noncompressive spinal cord syndromes. Ann Neurol (1987) 1.93
Antibody to human T-lymphotropic virus type 1 in West-Indian-born UK residents with spastic paraparesis. Lancet (1987) 1.92
Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology (1993) 1.87
Involvement of the central nervous system in chronic inflammatory demyelinating polyneuropathy: a clinical, electrophysiological and magnetic resonance imaging study. J Neurol Neurosurg Psychiatry (1990) 1.87
Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis. Lancet (1991) 1.86
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Mitochondrial encephalomyopathies: biochemical studies in two cases revealing defects in the respiratory chain. Brain (1982) 1.80
Primary progressive multiple sclerosis. Brain (1997) 1.80
The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol (1997) 1.73
B-lymphocyte alloantigens associated with multiple sclerosis. Lancet (1976) 1.73
Pathophysiology of demyelinating disease. Br Med Bull (1977) 1.70
Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain (1996) 1.69
Community services in multiple sclerosis: still a matter of chance. J Neurol Neurosurg Psychiatry (2000) 1.68
Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain (1994) 1.68
Neurological complications in Behçet's syndrome. Brain (1999) 1.68
Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat (2014) 1.68
Treatment of periodic alternating nystagmus. Ann Neurol (1980) 1.68
Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat (2014) 1.67
Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol (2000) 1.66
Evidence-based measurement: which disability scale for neurologic rehabilitation? Neurology (2001) 1.66
The significance of the association between HLA and multiple sclerosis. Br Med Bull (1978) 1.65
Interferon beta-1b. Lancet (1994) 1.64
Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry (2002) 1.64
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology (2008) 1.62
Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology (1998) 1.62
Transient uniocular visual loss on deviation of the eye in association with intraorbital tumours. J Neurol Neurosurg Psychiatry (1987) 1.61
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology (1997) 1.60
The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)--investigation of symptomatic and presymptomatic patients. Q J Med (1990) 1.60
Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology (1994) 1.60
Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry (2005) 1.59
High field MRI correlates of myelin content and axonal density in multiple sclerosis--a post-mortem study of the spinal cord. J Neurol (2003) 1.59
Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology (2001) 1.58
Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology (1999) 1.58
Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology (2001) 1.58
The symptomatology of tumours of the anterior visual pathways. Can J Neurol Sci (1982) 1.56
Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology (2010) 1.56